KATHMANDU, NEPAL — July 19, 2016 — The Sabin Vaccine Institute’s Sustainable Immunization Financing (SIF) Program today assembled senior officials from 21 countries to share their successes in increasing government budget allocations for national immunization programs. Greater political commitment and advocacy are building the momentum needed for countries to fully finance their immunization programs by 2020 and achieve the goals set forth in the Global Vaccine Action Plan (GVAP).
WASHINGTON, D.C. — June 22, 2016 — The Sabin Vaccine Institute is partnering with King Saud University (KSU) in Riyadh, Saudi Arabia, to advance vaccine research and development capacity in the Middle East and North Africa. As part of the new $6.6 million agreement, Saudi scientists will receive technical training in vaccine development at the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) laboratories in Houston, Texas.
Statement of Dr. Peter Hotez, President of the Sabin Vaccine Institute and Director of its Product Development Partnership on the Group of 7 (G7) Summit, at which the leaders of Japan, the United States, the United Kingdom, Germany, Canada, Italy and France affirmed a commitment to neglected tropical diseases (NTDs).
WASHINGTON, D.C. — May 2, 2016 — The Sabin Vaccine Institute (Sabin) today announced that Scott N. Wulfe, has joined its Board of Trustees. Mr. Wulfe is the managing partner of Vinson & Elkins LLP, an international law firm based in Houston.
WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.
KAMPALA, UGANDA — April 28, 2016 — The Sabin Vaccine Institute (Sabin) applauds the enactment of Uganda’s Immunization Act, 2016, which was recently signed into law by President Yoweri Museveni.
WASHINGTON, D.C. — April 19, 2016 — The Sabin Vaccine Institute (Sabin) will present the 2016 Albert B. Sabin Gold Medal Award to George R. Siber, M.D., chief scientific officer of ClearPath Vaccines Company.
WASHINGTON, D.C. — March 24, 2016 — The Sabin Vaccine Institute (Sabin) today announced the appointment of Amy Finan as its next chief executive officer, following a global search by its Board of Trustees.
Peter Hotez, M.D., Ph.D., president of Sabin, testified this week at two congressional hearings: the House Energy and Commerce Subcommittee on Oversight and Investigations hearing, “Examining the U.S. Public Health Response to the Zika Virus”; and the House Foreign Affairs Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations on “The Growing Threat of Cholera and Other Diseases in the Middle East.”
WASHINGTON, D.C. — Feb. 8, 2016 — On Monday, the World Health Organization (WHO) Director-General, Dr. Margaret Chan, declared Zika a Public Health Emergency International Concern (PHEIC), because of growing concerns of the suspected association between Zika and the rise in detected cases of congenital malformations and neurological complications in newborn babies.